Navigation Links
Researchers identify potential new therapeutic target for controlling high blood sugar
Date:3/19/2014

DALLAS March 19, 2014 A UT Southwestern Medical Center study has identified a new potential therapeutic target for controlling high blood sugar, a finding that could help the estimated 25 million Americans with type 2 diabetes.

Researchers showed that lipid molecules called phosphatidic acids enhance glucose production in the liver. These findings suggest that inhibiting or reducing production of phosphatidic acids may do the opposite.

This study establishes a role for phosphatidic acids in enhancing glucose production by the liver and identifies enzymes involved in the synthesis of phosphatidic acids as potential drug targets, said Dr. Anil Agarwal, Professor of Internal Medicine and senior author of the study in The Journal of Biological Chemistry.

These observations were made while studying a mouse model of lipodystrophy, a rare metabolic disease in which the body is devoid of fat. Lipodystrophy patients often develop diabetes and accumulate fat in the liver because of an imbalance in the bodys ability to properly regulate lipids and glucose. The causal gene, AGPAT2, which is involved in the synthesis of phosphatidic acid and triglycerides, was removed in the mice, resulting in rodents with generalized lipodystrophy. The research team then examined what impact this genetic manipulation had on phosphatidic acids and glucose production.

We expected the levels of phosphatidic acids to go down. However, in examining the livers of these lipodystrophic mice, we unexpectedly found high levels of this lipid class, Dr. Agarwal said, which led to the identification of new targets involved in the production of phosphatidic acids.

The buildup of these lipid molecules was due to an increase in the levels of two enzymes in the liver, diacylglycerol kinase and phospholipase D. Researchers also discovered a marked increase in glucose production in the livers of the lipodystrophic mice.

The lack of normal insulin signaling in these lipodystrophic mice led to unrestricted production of phosphatidic acid, Dr. Agarwal explained, contributing to development of hyperglycemia, or high blood sugar.

Besides revealing a new potential therapy to test for treatment of diabetes, the studys findings may have implications in understanding how cancer develops. Increased phosphatidic acid levels may play an important role in a metabolic pathway that supplies energy to cancer cells.

Lead author Dr. Shireesha Sankella, a postdoctoral researcher in the Division of Nutrition and Metabolic Diseases, now plans to test the inhibitors of diaclyglycerol kinase and phospholipase D in cultured cells and in animals to understand the molecular mechanisms for increased glucose production by phosphatidic acids in liver and cancer cells.


'/>"/>
Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Ottawa researchers find new pathway connected to type 2 diabetes
2. Shoulder revision repair surgery not as successful 2 years later, say researchers
3. Researchers find significant increase in painkillers prescribed to US adults in the ER
4. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
5. Researchers destroy cancer with cryoablation & nanoparticle-encapsulated anticancer drug
6. NYU researchers find majority of Latinas are unaware of their risk of diabetes
7. UF researchers find drug therapy that could eventually reverse memory decline in seniors
8. Researchers identify carbohydrates in a coal mine for cancer detection
9. Researchers X-ray living cancer cells
10. Fox Chase researchers discover new mechanism of gene regulation
11. Penn researchers show nuclear stiffness keeps stem cells and cancer cells in place
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers identify potential new therapeutic target for controlling high blood sugar
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal ... to the end of November. , The Chicago, Illinois, based self-defense brand has been ... them about the ease of taking their personal safety into their own hands. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing ... in compliance with FDA rules. , The FDA has issued two draft guidances ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and continued ... have been awarded five-year accreditation status through the Public Health Accreditation Board ... by a PHAB-accredited health department now extend to more than 203 million ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking with ... more holistic approach and use natural alternatives for all house cleaning products, disinfectants, ... USDA guaranteeing that, the new line of essential oils, are all 100% organic ...
(Date:9/21/2017)... ... 2017 , ... The New England Center for Children® (NECC®), a global leader ... Hung to the Board of Directors. , “The New England Center for Children ... an invaluable addition to our team,” said Vincent Strully, Jr., President and CEO of ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: